Niacin shows lower-than-expected risk for new-onset diabetes

03/7/2012 | Medscape (free registration)

A study of 942 patients with hyperlipemia showed the frequency of new-onset diabetes in those who took ezetimibe/simvastatin plus extended-release niacin was 3.5% at 64 weeks, a rate only "marginally higher" than 2.6% in those who had ezetimibe/simvastatin-only treatment. The findings appear in Diabetes Care.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN